Choosing the right ADC linker is one of the most consequential decisions in antibody-drug conjugate design, directly determining where and how a cytotoxic payload is released. The choice between cleavable and non-cleavable chemistries depends on tumor biology, target antigen behavior, payload mechanism, and the therapeutic window required. These questions address the core decision points buyers and researchers encounter when designing ADC programs.
What is the functional difference between a cleavable and a non-cleavable ADC linker?
Cleavable linkers are designed to release their payload in response to a specific intracellular or extracellular stimulus, such as low pH in lysosomes, elevated glutathione concentrations, or tumor-associated proteases. Non-cleavable linkers, by contrast, require complete lysosomal degradation of the antibody itself before the payload is liberated, releasing an amino acid-linker-payload metabolite rather than the free drug.
The practical consequence is that cleavable linkers can enable bystander killing, where released payload diffuses into neighboring tumor cells that may not express the target antigen. Non-cleavable linkers confine cytotoxic activity to antigen-positive cells, which reduces off-target exposure but also limits efficacy in heterogeneous tumors.
What types of cleavable linkers are used in ADC design, and how do they differ?
The three dominant cleavable linker chemistries are protease-cleavable (typically valine-citrulline or valine-alanine dipeptides recognized by cathepsin B), acid-labile (hydrazone bonds cleaved at endosomal pH of 4.5 to 5.5), and disulfide linkers (reduced by intracellular glutathione, which is 100 to 1,000-fold higher inside tumor cells than in plasma).
|
Linker Type |
Cleavage Trigger |
Stability in Circulation |
Bystander Effect |
|
Protease-cleavable (VC, VA) |
Cathepsin B / tumor proteases |
High |
Yes |
|
Acid-labile (hydrazone) |
Endosomal pH (4.5–5.5) |
Moderate |
Limited |
|
Disulfide |
Intracellular glutathione |
Moderate |
Limited |
|
Non-cleavable (SMCC, MC) |
Lysosomal antibody degradation |
Highest |
No |
Protease-cleavable linkers currently dominate approved and clinical-stage ADCs because they combine high plasma stability with efficient intracellular release. Acid-labile hydrazone linkers, used in earlier-generation ADCs, showed higher rates of premature payload release in circulation, which contributed to narrower therapeutic windows.
Is a “cleavable linker” the same as a “pH-sensitive linker”?
pH-sensitive linkers are one subset of cleavable linkers, not synonymous with the category. Cleavable linkers encompass any chemistry that responds to a biological stimulus, including proteases, redox gradients, and pH.
A protease-cleavable linker will not release payload efficiently in a tumor with low cathepsin B expression, regardless of the tumor’s pH profile. Selecting the correct cleavage mechanism requires characterizing the specific enzymatic and chemical environment of the target tissue before committing to a linker chemistry.
When should a cleavable linker be chosen over a non-cleavable linker?
Cleavable linkers are the preferred choice when the target antigen is heterogeneously expressed across the tumor, when bystander killing is needed to eliminate antigen-negative subpopulations, or when the payload must be released as the free drug to retain full potency. Solid tumors with poor antibody penetration particularly benefit from bystander activity, since not every cell will be reached by the ADC directly.
Non-cleavable linkers are better suited when the target antigen is uniformly expressed, when the payload retains activity as an amino acid conjugate, and when minimizing systemic payload exposure is the priority, for example in CNS-adjacent or highly vascularized indications where off-target toxicity is a dominant concern. The decision should be driven by antigen expression data, tumor histology, and the metabolic fate of the specific payload being used.
How does target antigen internalization rate affect linker choice?
Rapid and efficient antigen internalization is a prerequisite for both linker types to function, but it is especially critical for non-cleavable linkers. Non-cleavable linkers depend entirely on lysosomal trafficking and complete antibody catabolism to release the active metabolite, so slow or incomplete internalization directly reduces payload delivery.
Cleavable linkers, particularly protease-sensitive variants, can tolerate somewhat lower internalization efficiency because extracellular protease activity in the tumor microenvironment can contribute to payload release. For targets with moderate or variable internalization kinetics, cleavable linkers generally provide a more reliable release mechanism.
What role does the payload play in linker selection?
The payload’s mechanism of action and membrane permeability determine whether bystander killing is achievable and which linker class is compatible. Hydrophobic, membrane-permeable payloads such as MMAE (a tubulin inhibitor) diffuse freely across cell membranes after cleavage, enabling robust bystander killing when paired with a cleavable linker. Hydrophilic payloads such as DM1 (a maytansinoid used with non-cleavable SMCC linkers) produce charged metabolites after lysosomal degradation that are retained within the target cell.
The field is actively seeking novel linker-payload combinations to overcome patient resistance to current standard payloads including Topo1 inhibitors and MMAE, and to improve overall toxicology profiles. Matching payload chemistry to linker type is not optional: using a non-cleavable linker with a payload that requires free-drug release will substantially reduce potency regardless of antibody affinity or DAR optimization.
How do antibody format and size affect ADC linker design?
Antibody format directly constrains conjugation site availability and influences linker chemistry selection. Conventional IgG-based ADCs conjugate through lysine residues or reduced cysteines, producing heterogeneous drug-to-antibody ratios (DAR) that complicate pharmacokinetics and manufacturing consistency. Site-specific conjugation methods, including engineered cysteines and enzymatic approaches, produce defined DAR species with improved therapeutic windows.
Smaller antibody formats, including single-domain antibodies derived from HCAb technology, are gaining traction in ADC design because their reduced size (below approximately 40 kDa for the smallest formats) can enable renal clearance, which alters payload distribution and toxicology profiles compared to full IgG ADCs. Nona’s fully human antibody discovery capabilities include HCAb-derived binders that are compatible with these emerging fragment ADC formats, where linker chemistry must account for the faster clearance kinetics of smaller constructs.
What are the manufacturing and stability implications of each linker class?
Non-cleavable linkers generally offer superior plasma stability because they do not respond to any extracellular stimulus, reducing the risk of premature payload release during storage or circulation. This stability advantage simplifies CMC development and can reduce batch-to-batch variability in conjugation efficiency.
Cleavable linkers, particularly disulfide and hydrazone chemistries, require tighter control of manufacturing conditions, storage temperature, and formulation pH to prevent premature cleavage. Protease-cleavable linkers are more stable than earlier acid-labile designs but still require validation of stability under physiological plasma conditions. Nona’s CMC services include conjugation chemistry, DAR characterization, and stability profiling across both linker classes as part of IND-enabling package development.
How is resistance to current ADC payloads driving linker-payload innovation?
Tumor resistance to approved ADC payloads is an established clinical problem, with resistance mechanisms including target antigen downregulation, efflux pump upregulation, and payload-specific pathway bypass. Clients are actively seeking novel linker-payload combinations to address resistance to Topo1 inhibitors and MMAE, the two most widely used payload classes in current clinical ADCs.
Dual-payload ADC designs, which deliver two mechanistically distinct cytotoxic agents on a single antibody, represent one emerging strategy to prevent resistance by eliminating tumor subpopulations that survive single-payload exposure. Bispecific ADCs, which combine dual-antigen targeting with cytotoxic payload delivery, are another active area. Nona’s ADC linker and payload design expertise, including proprietary linker-payload patents, positions us to support programs requiring differentiated chemistry beyond standard VC-MMAE or DXd configurations.
What does an integrated ADC discovery program look like from antibody selection through linker-payload optimization?
An integrated ADC program begins with antibody discovery against the target antigen, followed by selection of candidates with the internalization kinetics, epitope accessibility, and biophysical properties required for conjugation. Linker-payload selection is then matched to the antigen biology, tumor microenvironment, and payload mechanism established in the discovery phase.
Our I-to-I® (Nona’s integrated end-to-end service pathway from ideation through IND filing) covers target validation, antibody discovery using Harbour Mice® (transgenic mice engineered to produce fully human vs humanized monoclonal antibody candidates in both H2L2 and heavy-chain-only formats), linker-payload design, conjugation, and preclinical pharmacology through to IND-enabling toxicology. With over 300 antibody discovery programs completed and 19 or more clinical-stage molecules, including the Pfizer MesoC2 ADC program presented at ASCO, we bring validated ADC experience across the full discovery-to-IND continuum. Researchers designing ADC programs can engage our team at the antibody discovery stage to ensure that linker-payload selection is informed by the same antigen characterization data used to select the lead antibody.
Linker selection is ultimately an integrated decision: the cleavage mechanism, payload chemistry, antigen internalization kinetics, and tumor microenvironment all constrain each other, and optimizing one variable in isolation tends to surface problems downstream in CMC or the clinic. As the field moves toward dual-payload designs and novel warhead classes beyond VC-MMAE and DXd, linker chemistry will need to keep pace, matching release kinetics and metabolite profiles to payloads that behave very differently from the first-generation standards.
Nona’s ADC linker and payload design capabilities, including proprietary linker-payload patents, are built into the same discovery-to-IND continuum as the antibody selection process — so that linker chemistry decisions are made against the same antigen characterization data used to select the lead candidate, not after the fact.
-
P. Doronina S. et al., Development of potent monoclonal antibody auristatin conjugates for cancer therapy, Nature Biotechnology, 2003. Link
-
J. Lambert M. et al., Drug-conjugated antibodies for the treatment of cancer, British Journal of Clinical Pharmacology, 2013. Link
-
A. Beck et al., Strategies and challenges for the next generation of antibody-drug conjugates, Nature Reviews Drug Discovery, 2017. Link
-
N. Diamantis et al., Antibody-drug conjugates — an emerging class of cancer treatment, British Journal of Cancer, 2016. Link
-
L. Ducry et al., Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies, Bioconjugate Chemistry, 2010. Link
-
G. Casi et al., Antibody-drug conjugates: basic concepts, examples and future perspectives, Journal of Controlled Release, 2012. Link
-
J. Flygare et al., Antibody-drug conjugates for the treatment of cancer, Chemical Biology and Drug Design, 2013. Link
-
S. Verma et al., Trastuzumab emtansine for HER2-positive advanced breast cancer, New England Journal of Medicine, 2012. Link
-
G. Casi et al., Protease-Cleavable Linkers Modulate the Anticancer Activity of Non-Internalizing Antibody-Drug Conjugates, PMC, 2017. Link
-
K. Kolodych et al., Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates, PMC, 2023. Link
